OBJECTIVE: Up to 12% of all endometrial-carcinomas (EC) harbor DNA-polymerase-ε-(POLE) mutations. It is currently unknown whether the favorable prognosis of POLE-mutated EC is derived from their low metastatic capability, extraordinary number of somatic mutations thus imparting immunogenicity, or a high sensitivity to chemotherapy. METHODS: Polymerase-chain-reaction-amplification and Sanger-sequencing were used to test for POLE exonuclease-domain-mutations (exons 9-14) 131 EC. Infiltration of CD4+ and CD8+ T-lymphocytes (TIL) and PD-1-expression in POLE-mutated vs POLE wild-type EC was studied by immunohistochemistry (IHC) and the correlations between survival and molecular features were investigated. Finally, primary POLE-mutated and POLE-wild-type EC cell lines were established and compared in-vitro for their sensitivity to chemotherapy. RESULTS: Eleven POLE-mutated EC (8.5%) were identified. POLE-mutated tumors were associated with improved progression-free-survival (P<0.05) and displayed increased numbers of CD4+ (44.5 vs 21.8; P=0.001) and CD8+ (32.8 vs 13.5; P<0.001) TILs when compared to wild-type POLE EC. PD-1 receptor was overexpressed in TILs from POLE-mutated vs wild-type-tumors (81% vs 28%; P<0.001). Primary POLE tumor cell lines were significantly more resistant to platinum-chemotherapy in-vitro when compared to POLE-wild-type tumors (P<0.004). CONCLUSIONS: POLE ultra-mutated EC are heavily infiltrated with CD4+/CD8+ TIL, overexpress PD-1 immune-check-point (i.e., features consistent with chronic antigen-exposure), and have a better prognosis when compared to other molecular subtypes of EC patients. POLE-mutated tumor-cell lines are resistant to platinum-chemotherapy in-vitro suggesting that the better prognosis of POLE-patients is not secondary to a higher sensitivity to chemotherapy but likely linked to enhanced immunogenicity.
OBJECTIVE: Up to 12% of all endometrial-carcinomas (EC) harbor DNA-polymerase-ε-(POLE) mutations. It is currently unknown whether the favorable prognosis of POLE-mutated EC is derived from their low metastatic capability, extraordinary number of somatic mutations thus imparting immunogenicity, or a high sensitivity to chemotherapy. METHODS: Polymerase-chain-reaction-amplification and Sanger-sequencing were used to test for POLE exonuclease-domain-mutations (exons 9-14) 131 EC. Infiltration of CD4+ and CD8+ T-lymphocytes (TIL) and PD-1-expression in POLE-mutated vs POLE wild-type EC was studied by immunohistochemistry (IHC) and the correlations between survival and molecular features were investigated. Finally, primary POLE-mutated and POLE-wild-type EC cell lines were established and compared in-vitro for their sensitivity to chemotherapy. RESULTS: Eleven POLE-mutated EC (8.5%) were identified. POLE-mutated tumors were associated with improved progression-free-survival (P<0.05) and displayed increased numbers of CD4+ (44.5 vs 21.8; P=0.001) and CD8+ (32.8 vs 13.5; P<0.001) TILs when compared to wild-type POLE EC. PD-1 receptor was overexpressed in TILs from POLE-mutated vs wild-type-tumors (81% vs 28%; P<0.001). Primary POLE tumor cell lines were significantly more resistant to platinum-chemotherapy in-vitro when compared to POLE-wild-type tumors (P<0.004). CONCLUSIONS: POLE ultra-mutated EC are heavily infiltrated with CD4+/CD8+ TIL, overexpress PD-1 immune-check-point (i.e., features consistent with chronic antigen-exposure), and have a better prognosis when compared to other molecular subtypes of EC patients. POLE-mutated tumor-cell lines are resistant to platinum-chemotherapy in-vitro suggesting that the better prognosis of POLE-patients is not secondary to a higher sensitivity to chemotherapy but likely linked to enhanced immunogenicity.
Authors: Bo Meng; Lien N Hoang; John B McIntyre; Máire A Duggan; Gregg S Nelson; Cheng-Han Lee; Martin Köbel Journal: Gynecol Oncol Date: 2014-05-16 Impact factor: 5.482
Authors: Siming Zhao; Murim Choi; John D Overton; Stefania Bellone; Dana M Roque; Emiliano Cocco; Federica Guzzo; Diana P English; Joyce Varughese; Sara Gasparrini; Ileana Bortolomai; Natalia Buza; Pei Hui; Maysa Abu-Khalaf; Antonella Ravaggi; Eliana Bignotti; Elisabetta Bandiera; Chiara Romani; Paola Todeschini; Renata Tassi; Laura Zanotti; Luisa Carrara; Sergio Pecorelli; Dan-Arin Silasi; Elena Ratner; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Amy L Stiegler; Shrikant Mane; Titus J Boggon; Joseph Schlessinger; Richard P Lifton; Alessandro D Santin Journal: Proc Natl Acad Sci U S A Date: 2013-01-28 Impact factor: 11.205
Authors: Tina M Albertson; Masanori Ogawa; James M Bugni; Laura E Hays; Yang Chen; Yanping Wang; Piper M Treuting; John A Heddle; Robert E Goldsby; Bradley D Preston Journal: Proc Natl Acad Sci U S A Date: 2009-09-24 Impact factor: 11.205
Authors: Emily Rayner; Inge C van Gool; Claire Palles; Stephen E Kearsey; Tjalling Bosse; Ian Tomlinson; David N Church Journal: Nat Rev Cancer Date: 2016-02 Impact factor: 60.716
Authors: Claire Palles; Jean-Baptiste Cazier; Kimberley M Howarth; Enric Domingo; Angela M Jones; Peter Broderick; Zoe Kemp; Sarah L Spain; Estrella Guarino; Estrella Guarino Almeida; Israel Salguero; Amy Sherborne; Daniel Chubb; Luis G Carvajal-Carmona; Yusanne Ma; Kulvinder Kaur; Sara Dobbins; Ella Barclay; Maggie Gorman; Lynn Martin; Michal B Kovac; Sean Humphray; Anneke Lucassen; Christopher C Holmes; David Bentley; Peter Donnelly; Jenny Taylor; Christos Petridis; Rebecca Roylance; Elinor J Sawyer; David J Kerr; Susan Clark; Jonathan Grimes; Stephen E Kearsey; Huw J W Thomas; Gilean McVean; Richard S Houlston; Ian Tomlinson Journal: Nat Genet Date: 2012-12-23 Impact factor: 38.330
Authors: Munveer S Bhangoo; Peter Boasberg; Pareen Mehta; Julia A Elvin; Siraj M Ali; Winnie Wu; Samuel J Klempner Journal: Oncologist Date: 2018-01-31
Authors: Sara Imboden; Denis Nastic; Mehran Ghaderi; Filippa Rydberg; Tilman T Rau; Michael D Mueller; Elisabeth Epstein; Joseph W Carlson Journal: PLoS One Date: 2019-03-27 Impact factor: 3.240
Authors: Clara Degos; Mellie Heinemann; Julien Barrou; Nicolas Boucherit; Eric Lambaudie; Ariel Savina; Laurent Gorvel; Daniel Olive Journal: Front Immunol Date: 2019-04-26 Impact factor: 7.561
Authors: Holly Lindsay; Sarah Scollon; Jacquelyn Reuther; Horatiu Voicu; Surya P Rednam; Frank Y Lin; Kevin E Fisher; Murali Chintagumpala; Adekunle M Adesina; D Will Parsons; Sharon E Plon; Angshumoy Roy Journal: Cold Spring Harb Mol Case Stud Date: 2019-10-23